These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15011605)

  • 1. [Managing side effects. Individualized dosage makes indinavir more tolerable].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():84. PubMed ID: 15011605
    [No Abstract]   [Full Text] [Related]  

  • 2. [A plea for an individualized therapy regimen. Which is the optimal dose?].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():26-7. PubMed ID: 12043067
    [No Abstract]   [Full Text] [Related]  

  • 3. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 4. Brazil indinavir results releases.
    AIDS Patient Care STDS; 1997 Dec; 11(6):457. PubMed ID: 11361873
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report.
    Lee SI; Klesmer J; Hirsch BE
    Psychosomatics; 2000; 41(5):453-4. PubMed ID: 11015640
    [No Abstract]   [Full Text] [Related]  

  • 6. Different combinations of ritonavir-indinavir.
    TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
    [No Abstract]   [Full Text] [Related]  

  • 7. [A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():57. PubMed ID: 15011592
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
    J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New AIDS study confirms: triple combination therapy with the protease inhibitor indinavir lowers the risk of mortality by 50%].
    Praxis (Bern 1994); 1997 May; 86(20):860. PubMed ID: 9312815
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA clearance for ritonavir in children with AIDS.
    AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361797
    [No Abstract]   [Full Text] [Related]  

  • 11. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy.
    Gilquin J; Viard JP; Jubault V; Sert C; Kazatchkine MD
    Lancet; 1998 Dec; 352(9144):1907-8. PubMed ID: 9863795
    [No Abstract]   [Full Text] [Related]  

  • 13. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indinavir-associated lipodystrophy].
    Krautheim A
    Praxis (Bern 1994); 1999 Feb; 88(7):285-7. PubMed ID: 10097649
    [No Abstract]   [Full Text] [Related]  

  • 15. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
    Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effective in HIV: dual combination with indinavir and ritonavir].
    Dtsch Med Wochenschr; 2001 May; 126(18):A411. PubMed ID: 11381644
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment.
    Pan SC; Hsieh SM; Hung CC; Huang PF; Chen MY; Chang SC
    J Microbiol Immunol Infect; 2005 Feb; 38(1):31-4. PubMed ID: 15692624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching HIV-1 protease inhibitor therapy: which? When? And why?
    Guardiola JM; Domingo P; Vazquez G
    Arch Intern Med; 1999 Jan; 159(2):194-5. PubMed ID: 9927104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.